Polar Capital LLP cut its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 25.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,569 shares of the company’s stock after selling 116,733 shares during the period. Polar Capital LLP owned 0.80% of Zogenix worth $12,198,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Zogenix by 20.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,956 shares of the company’s stock worth $108,000 after buying an additional 496 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Zogenix during the 3rd quarter worth approximately $109,000. FNY Investment Advisers LLC boosted its holdings in shares of Zogenix by 3,900.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock worth $148,000 after buying an additional 2,925 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of Zogenix by 44.9% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,382 shares of the company’s stock worth $189,000 after buying an additional 1,668 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Zogenix during the 3rd quarter worth approximately $219,000.

A number of equities analysts have issued reports on the company. Guggenheim assumed coverage on Zogenix in a report on Friday, February 22nd. They set a “buy” rating and a $70.00 price target on the stock. Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, January 12th. BidaskClub upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Finally, Mizuho restated a “buy” rating and set a $69.00 price target on shares of Zogenix in a report on Thursday, December 6th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $70.00.

In related news, CEO Stephen J. Farr sold 90,313 shares of the stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $45.00, for a total value of $4,064,085.00. Following the transaction, the chief executive officer now directly owns 52,259 shares in the company, valued at approximately $2,351,655. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Renee P. Tannenbaum sold 17,503 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $50.65, for a total value of $886,526.95. Following the completion of the transaction, the director now owns 19,375 shares in the company, valued at $981,343.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 141,096 shares of company stock worth $6,575,536. 4.60% of the stock is owned by company insiders.

Shares of ZGNX opened at $52.63 on Friday. Zogenix, Inc. has a 12-month low of $33.43 and a 12-month high of $62.75. The firm has a market capitalization of $2.22 billion, a P/E ratio of -16.29 and a beta of 2.18.

ILLEGAL ACTIVITY WARNING: “Polar Capital LLP Has $12.20 Million Position in Zogenix, Inc. (ZGNX)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2019/03/15/polar-capital-llp-has-12-20-million-position-in-zogenix-inc-zgnx.html.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

See Also: Diversification Important in Investing

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.